| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
IRAK4 4 μM (IC50)
Interleukin-1 receptor-associated kinase 4 (IRAK-4). IRAK-4 is a serine/threonine kinase that plays a critical role in the signaling pathways of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). Upon receptor activation, IRAK-4 is recruited to the receptor complex, where it phosphorylates and activates downstream signaling molecules, leading to the activation of NF-κB and MAPK pathways and the production of pro-inflammatory cytokines. IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of IRAK-4 with an IC50 of 4 μM. By inhibiting IRAK-4, the compound blocks TLR and IL-1R signaling, reducing the production of pro-inflammatory mediators and attenuating the inflammatory response. |
|---|---|
| ln Vitro |
Compound 1, IRAK-4 protein kinase inhibitor 2, likewise inhibits IRAK-1, with an IC50 of less than 10 μM[1].
In vitro, IRAK-4 protein kinase inhibitor 2 is a potent inhibitor of IRAK-4 with an IC50 of 4 μM. The compound effectively inhibits IRAK-4 kinase activity, blocking downstream signaling through NF-κB and MAPK pathways. In cell-based assays, the compound inhibits the production of pro-inflammatory cytokines in response to TLR or IL-1R stimulation. |
| ln Vivo |
In vivo, IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders. By inhibiting IRAK-4, the compound may reduce inflammation and tissue damage in various disease models. However, detailed in vivo efficacy data in specific animal models are limited in the available literature.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (cell-free) assay for IRAK-4 protein kinase inhibitor 2 typically involves measuring the inhibition of IRAK-4 kinase activity using purified recombinant IRAK-4 enzyme. The assay is performed by incubating IRAK-4 with a peptide substrate and ATP in the presence of varying concentrations of the compound. The phosphorylation of the substrate is measured using a luminescent or fluorescent detection method, and the IC50 for IRAK-4 inhibition is determined from dose-response curves. Selectivity assays can be performed to assess the compound's activity against other kinases.
|
| Cell Assay |
In vitro cellular assays for IRAK-4 protein kinase inhibitor 2 are performed using cell lines that express IRAK-4 and respond to TLR or IL-1R stimulation. Cells are treated with varying concentrations of the compound and stimulated with a TLR agonist (such as LPS) or IL-1β. The production of pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β) is measured in the culture supernatant by ELISA. The inhibition of IRAK-4-mediated signaling can be assessed by measuring the phosphorylation of downstream signaling molecules, such as IRAK1, TAK1, or IKK.
|
| Animal Protocol |
In vivo animal experiments for IRAK-4 protein kinase inhibitor 2 would typically be conducted in rodent models of inflammatory and immune-related conditions. The compound is administered via oral gavage or intraperitoneal injection at various dose levels. Inflammatory cytokine levels in serum or tissues are measured by ELISA. Histopathological analysis of affected tissues is performed to assess tissue damage. The compound's ability to reduce inflammation and tissue damage is determined by its effects on inflammatory marker levels and histopathological scores.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for IRAK-4 protein kinase inhibitor 2 are limited. As a small molecule with a molecular weight of 282.25 g/mol and a molecular formula of C14H10N4O3, the compound is expected to have moderate oral bioavailability and tissue distribution. Further pharmacokinetic studies would be required to fully characterize its absorption, distribution, metabolism, and excretion (ADME) properties, including half-life, Cmax, AUC, and clearance.
|
| Toxicity/Toxicokinetics |
Toxicology data for IRAK-4 protein kinase inhibitor 2 are limited. The compound is used for research purposes only and is not approved for human use. No significant toxicities have been reported in the available literature. As an IRAK-4 inhibitor, the compound may have immunomodulatory effects that could impact host defense against infections. Careful evaluation of safety and potential off-target effects would be required for therapeutic development.
|
| References | |
| Additional Infomation |
IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of IRAK-4 with an IC50 of 4 μM. It has a CAS number of 301675-24-1, a molecular formula of C14H10N4O3, and a molecular weight of 282.25. The compound can be used for the research of inflammatory and immune-related conditions or disorders. IRAK-4 protein kinase inhibitor 2 is not approved for human use and is intended for research purposes only.
|
| Molecular Formula |
C14H10N4O3
|
|---|---|
| Molecular Weight |
282.25
|
| Exact Mass |
282.075
|
| CAS # |
301675-24-1
|
| PubChem CID |
3572750
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.63
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
412
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)NC(=N2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
|
| InChi Key |
QPKROMNIEAEFQA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H10N4O3/c19-13(9-4-3-5-10(8-9)18(20)21)17-14-15-11-6-1-2-7-12(11)16-14/h1-8H,(H2,15,16,17,19)
|
| Chemical Name |
N-(1H-benzimidazol-2-yl)-3-nitrobenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (35.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (3.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5430 mL | 17.7148 mL | 35.4296 mL | |
| 5 mM | 0.7086 mL | 3.5430 mL | 7.0859 mL | |
| 10 mM | 0.3543 mL | 1.7715 mL | 3.5430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
